Developing science,
delivering therapies
Our company
We are pioneers in harnessing bacteria as a revolutionary new class of medicines β called live biotherapeutics.
Our approachDeveloping science
From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.
What we doDelivering therapies
We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.
Find out moreNews
4D pharma’s Blautix® Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics
4D pharma today presented new biomarker data from two ongoing clinical trials of its lead immuno-oncology single strain Live Biotherapeutic, MRx0518, at the at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting (SITC 2022).
4D pharma plc (AIM: DDDD) today announces two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting (SITC 2022), held from November 8-12, 2022. The two e-posters will be available from 2.00 pm GMT (9.00 am ET) on November 10, 2022, via the 4D pharma website at https://www.4dpharmaplc.com.
BACK TO TOP